Found: 20
Select item for more details and to access through your institution.
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 204, n. 2, p. 289, doi. 10.1007/s10549-023-07195-5
- By:
- Publication type:
- Article
Body composition and breast cancer risk and treatment: mechanisms and impact.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 186, n. 2, p. 273, doi. 10.1007/s10549-020-06092-5
- By:
- Publication type:
- Article
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 183, n. 3, p. 729, doi. 10.1007/s10549-020-05837-6
- By:
- Publication type:
- Article
Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 179, n. 2, p. 435, doi. 10.1007/s10549-019-05467-7
- By:
- Publication type:
- Article
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 171, n. 2, p. 501, doi. 10.1007/s10549-018-4853-4
- By:
- Publication type:
- Article
Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 3, p. 1025, doi. 10.1002/cam4.2780
- By:
- Publication type:
- Article
Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 1, p. 41, doi. 10.1002/cam4.571
- By:
- Publication type:
- Article
Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
- Published in:
- PLoS ONE, 2021, v. 16, n. 4, p. 1, doi. 10.1371/journal.pone.0250057
- By:
- Publication type:
- Article
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
- Published in:
- Biomedicines, 2023, v. 11, n. 3, p. 735, doi. 10.3390/biomedicines11030735
- By:
- Publication type:
- Article
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
- Published in:
- Biomedicines, 2021, v. 9, n. 7, p. 740, doi. 10.3390/biomedicines9070740
- By:
- Publication type:
- Article
A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4839, doi. 10.3390/cancers13194839
- By:
- Publication type:
- Article
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2650, doi. 10.3390/cancers13112650
- By:
- Publication type:
- Article
The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy.
- Published in:
- Cancers, 2021, v. 13, n. 4, p. 608, doi. 10.3390/cancers13040608
- By:
- Publication type:
- Article
Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3105, doi. 10.3390/cancers12113105
- By:
- Publication type:
- Article
Targeting Signaling Pathways in Inflammatory Breast Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2479, doi. 10.3390/cancers12092479
- By:
- Publication type:
- Article
Advanced small-cell colon carcinoma: a case report.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 7, n. 6, p. 1079, doi. 10.3892/mco.2017.1464
- By:
- Publication type:
- Article
An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 6, n. 2, p. 266, doi. 10.3892/mco.2016.1101
- By:
- Publication type:
- Article
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
- Published in:
- 2019
- By:
- Publication type:
- journal article